Malignant neoplasm of breast
|
0.800 |
CausalMutation
|
disease |
CGI |
|
|
|
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
MGD |
|
|
|
Malignant neoplasm of breast
|
0.800 |
GenomicAlterations
|
disease |
CGI |
|
|
|
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer.
|
3798106 |
1987 |
Malignant neoplasm of breast
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the estrogen and progesterone receptors and the oncogene ERBB2.
|
3321071 |
1987 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
Amplification of c-erbB-2 was found in 15 of 86 primary breast cancers and in 3 of 12 secondary breast cancers.
|
3664511 |
1987 |
Malignant neoplasm of breast
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.
|
2903446 |
1988 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
This is the first study showing that a determination of the level of c-erbB-2 protein in paraffin-embedded tumor sections may have prognostic value for the course of human breast cancer.
|
2893663 |
1988 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
Therefore, immuno-histological diagnosis with anti-c-erbB-2 antibody might be useful as an indicator to predict lymph-node involvement in breast cancer.
|
2576425 |
1989 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
The HER-2/neu proto-oncogene is amplified in 25 to 30 percent of human primary breast cancers and this alteration is associated with disease behavior.
|
2470152 |
1989 |
Malignant neoplasm of breast
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Five proto-oncogenes were found to be occasionally amplified in primary breast cancers: c-ERBB-2 (11%), c-MYB (3%), c-RAS-Ki (3%), INT-2 (4%) and c-MYC (6%).
|
2915899 |
1989 |
Malignant neoplasm of breast
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Heterogeneous expression of erbB-2 messenger RNA in human breast cancer.
|
2568168 |
1989 |
Malignant neoplasm of breast
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Membrane protein levels of erbB-2 and epidermal growth factor (EGF) receptor as well as gene aberrations affecting these proto-oncogenes in human mammary cancer were determined in primary and metastatic lesions.
|
2564657 |
1989 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
Correlation of erbB-2 gene amplification with low levels of estrogen and/or progesterone receptors in primary breast cancer: do erbB-2 products delineate hormone-independent tumors?
|
2696563 |
1989 |
Malignant neoplasm of breast
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
The c-myc gene was amplified 5-7-fold in two adenocarcinomas, the H-ras gene 3 5-fold in one adenocarcinoma, while the K-ras and the neu gene were amplified in lung metastases from a colorectal and a breast cancer primary respectively.
|
2547415 |
1989 |
Malignant neoplasm of breast
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
These findings confirm and extend earlier results of studies of int-2, c-erbB-2 and c-myc amplification in human breast cancers and point to a role for int-2 activation in certain cases of recurrent breast malignant neoplasia.
|
2611995 |
1989 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
Some of these mutations involve amplification of protooncogenes (c-myc, c-erbB-2, and int-2) that have been shown to contribute to experimentally induced breast cancer in mouse model systems.
|
2667653 |
1989 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
About 40% of breast carcinomas contain either amplified c-myc or c-erbB-2 protooncogenes, whereas simultaneous amplification of both was seen in only one sample, suggesting the involvement of two distinct molecular mechanisms in breast cancer.
|
2573420 |
1989 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
HER-2/neu oncogene protein and prognosis in breast cancer.
|
2569032 |
1989 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
Alterations in the gene copy numbers of the proto-oncogenes HER2/neu and c-myc in primary human breast cancer investigated in 73 patients.
|
2563720 |
1989 |
Malignant neoplasm of breast
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Amplification and over-expression of the c-erbB-2 proto-oncogene were observed in 27% and 47% of tumors, respectively, and were strongly associated with breast cancers of the most unfavorable prognosis, namely IBC and NBC with multiple positive axillary nodes.
|
2563719 |
1989 |
Malignant neoplasm of breast
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Since overexpression of HER2/neu oncogenes in breast cancer cells is associated with resistance to the cytotoxic effect of tumor necrosis factor (TNF), we investigated whether this correlation also existed for ovarian cancer targets.
|
1977519 |
1990 |
Malignant neoplasm of breast
|
0.800 |
Biomarker
|
disease |
BEFREE |
Amplification of the Neu oncogene (c-erbB-2) has been reported by various researchers as a marker for poor clinical outcome in patients with breast cancer.
|
1977159 |
1990 |
Malignant neoplasm of breast
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer.
|
1967930 |
1990 |
Malignant neoplasm of breast
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Among the neoplasms assayed p185 HER2 was expressed in 46% of primary breast cancers, in 28% of ovarian tumors and in 30% of colon rectum malignancies.
|
1968437 |
1990 |